Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

Rhea-AI Summary

Biodesix (NASDAQ: BDSX), a leading diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will participate in the fireside chat at Cowen’s 43rd Annual Healthcare Conference from March 6-8, 2023. The chat is scheduled for March 7 at 1:30 PM ET at Boston Marriott Copley Place. It will also be webcast live on the company's website. Biodesix leverages AI to develop diagnostic tests for lung diseases, offering five Medicare-covered tests, including Nodify Lung and IQLung strategies, which aid in assessment and treatment of lung diseases. For more details, visit biodesix.com.

BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person 1x1 investor meetings at Cowen’s 43rd Annual Healthcare Conference being held from March 6-8, 2023.

Cowen’s 43rd Annual Healthcare Conference
Fireside Chat Date: Tuesday, March 7, 2023
Fireside Chat Time: 1:30 PM ET
Location: Boston Marriott Copley Place

The fireside chat will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at www.biodesix.com.

About Biodesix
Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung^® nodule risk assessment testing strategy, consisting of the Nodify XL2^® and the Nodify CDT^® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat^® targeted ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex^® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005454/en/

Media:

Robin Harper Cowie

robin.cowie@biodesix.com

(720) 509-8841

Investors:

Chris Brinzey

chris.brinzey@westwicke.com

(339) 970-2843

Source: Biodesix, Inc.

FAQ

When will Scott Hutton speak at the Cowen Healthcare Conference?

Scott Hutton will speak at the Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 1:30 PM ET.

What is the focus of Biodesix?

Biodesix focuses on data-driven diagnostic solutions for lung diseases.

Where can I watch the Biodesix fireside chat?

The fireside chat will be webcast live on Biodesix's website under the 'News & Events' section.

What tests does Biodesix offer for lung diseases?

Biodesix offers five Medicare-covered tests, including Nodify XL2 and GeneStrat, designed for lung disease risk assessment and treatment decision support.

What is the location of the Cowen Healthcare Conference?

The Cowen Healthcare Conference will be held at Boston Marriott Copley Place.